Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios Dimopoulos

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Drugs|May 22, 2016
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
The Oncologist|May 11, 2012
European perspective on multiple myeloma treatment strategies: update following recent congressesHeinz Ludwig, Hervé Avet-Loiseau, Joan Bladé, et al.
The Oncologist|January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Drugs|May 22, 2016
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.
Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
The Oncologist|May 11, 2012
European perspective on multiple myeloma treatment strategies: update following recent congressesHeinz Ludwig, Hervé Avet-Loiseau, Joan Bladé, et al.
The Oncologist|January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Pageof 12